Oral thin films Synergy28 Jan 2026 20:06
The OTF delivery system could turn out to be a goldmine.
What's next??
Solvonis said SVN-015 is expected to be developed as a once-daily oral therapy suitable for at-home use, aligned with standard antidepressant treatment cycles, and noted the compound has also been selected for evaluation in the US National Institute on Drug Abuse Addiction Treatment Discovery Program for stimulant use disorders.
Solvonis Therapeutics plc (LON: SVNS), ("Solvonis" or the "Company") an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce that Awakn Life Sciences Corp. ("Awakn"), the company Solvonis plans to acquire, has reached a significant regulatory milestone. Awakn announced a positive outcome from a Pre-Investigational New Drug ("Pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") regarding AWKN-002, a proprietary oral thin film ("OTF") formulation of esketamine, designed for sublingual and buccal administration in combination with structured alcohol education. This drug candidate is being developed for the treatment of moderate to severe alcohol use disorder ("AUD") with a focus on U.S market